Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages -
Publisher
American Chemical Society (ACS)
Online
2022-05-13
DOI
10.1021/acs.jmedchem.1c02214
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS‐CoV‐2 Papain‐Like Protease
- (2022) Lennart Brewitz et al. ChemMedChem
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting SARS‐CoV‐2 Viral Proteases as a Therapeutic Strategy to Treat COVID‐19
- (2021) Varada Anirudhan et al. JOURNAL OF MEDICAL VIROLOGY
- Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
- (2021) Gordon J. Lockbaum et al. Viruses-Basel
- Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
- (2021) Julian Breidenbach et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
- (2021) Cheng Liu et al. ANTIVIRAL RESEARCH
- SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
- (2021) Jingxin Qiao et al. SCIENCE
- Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2
- (2021) Wenhao Dai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Viral Proteases as Targets for COVID-19 Drug Development
- (2021) Wei Zhu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
- (2021) Sebastian Günther et al. SCIENCE
- SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
- (2021) Andrea Citarella et al. Biomolecules
- Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals
- (2021) Le-Yun Sun et al. BIOORGANIC CHEMISTRY
- Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)
- (2021) Sang Hoon Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies
- (2021) Arun K. Ghosh et al. JOURNAL OF MEDICINAL CHEMISTRY
- 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents
- (2021) Sho Konno et al. JOURNAL OF MEDICINAL CHEMISTRY
- Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
- (2021) Bing Bai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease
- (2021) Chamandi S. Dampalla et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rational design of a new antibiotic class for drug-resistant infections
- (2021) Thomas F. Durand-Reville et al. NATURE
- DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors
- (2021) Srinivas Chamakuri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease
- (2021) Maya G. Deshmukh et al. STRUCTURE
- Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
- (2021) Martin A. Redhead et al. Scientific Reports
- Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay
- (2021) Tonko Dražić et al. SLAS Discovery
- Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use
- (2021) Davide Carcione et al. Antibiotics-Basel
- Structure‐Activity Studies Reveal Scope for Optimisation of Ebselen‐Type Inhibition of SARS‐CoV‐2 Main Protease
- (2021) Siegfried T. D. Thun‐Hohenstein et al. ChemMedChem
- Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors
- (2021) Julia K. Stille et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Perspectives on SARS-CoV-2 Main Protease Inhibitors
- (2021) Kaifu Gao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
- (2021) Chunlong Ma et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- DIALS as a toolkit
- (2021) Graeme Winter et al. PROTEIN SCIENCE
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors
- (2021) Dmitriy Shcherbakov et al. ACS Medicinal Chemistry Letters
- Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
- (2021) Yao Zhao et al. Protein & Cell
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
- (2020) Nature Microbiology
- Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
- (2020) Arun K. Ghosh et al. ChemMedChem
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
- (2020) Zachary A. Gurard-Levin et al. ANTIVIRAL RESEARCH
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- (2020) Robert L. Hoffman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
- (2020) Lifeng Fu et al. Nature Communications
- Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
- (2020) Alice Douangamath et al. Nature Communications
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2020) Wayne Vuong et al. Nature Communications
- A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**
- (2020) Kai S. Yang et al. ChemMedChem
- A Fluorescence‐based Assay for Screening β‐Lactams Targeting the Mycobacterium tuberculosis Transpeptidase LdtMt2
- (2019) Mariska de Munnik et al. CHEMBIOCHEM
- β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs
- (2019) Concepción González-Bello et al. JOURNAL OF MEDICINAL CHEMISTRY
- Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes
- (2019) Tonko Dražić et al. JOURNAL OF MEDICINAL CHEMISTRY
- CCP4i2: the new graphical user interface to the CCP4 program suite
- (2018) Liz Potterton et al. Acta Crystallographica Section D-Structural Biology
- Binding and processing of β-lactam antibiotics by the transpeptidase LdtMt2fromMycobacterium tuberculosis
- (2017) Eva Maria Steiner et al. FEBS Journal
- AceDRG: a stereochemical description generator for ligands
- (2017) Fei Long et al. Acta Crystallographica Section D-Structural Biology
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
- (2016) David Yuxin Wang et al. Future Medicinal Chemistry
- An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
- (2016) Thanigaimalai Pillaiyar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Non-classical transpeptidases yield insight into new antibacterials
- (2016) Pankaj Kumar et al. Nature Chemical Biology
- How good are my data and what is the resolution?
- (2013) Philip R. Evans et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Decision making inxia2
- (2013) Graeme Winter et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- In VitroCross-Linking of Mycobacterium tuberculosis Peptidoglycan by l,d-Transpeptidases and Inactivation of These Enzymes by Carbapenems
- (2013) Mathilde Cordillot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Recent Trends in the Design, Synthesis and Biological Exploration of β-Lactams
- (2013) G. Veinberg et al. CURRENT MEDICINAL CHEMISTRY
- PDB_REDO: constructive validation, more than just looking for errors
- (2012) Robbie P. Joosten et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Exploiting structure similarity in refinement: automated NCS and target-structure restraints inBUSTER
- (2012) Oliver S. Smart et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Synthesis and Crystal of Methyl 6,6-dihydropenicillanate S,S-dioxide
- (2012) H.-L. Zhang et al. Synthesis and Reactivity in Inorganic Metal-Organic and Nano-Metal Chemistry
- Molecular replacement withMOLREP
- (2009) Alexei Vagin et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- COMU: A third generation of uronium-type coupling reagents
- (2009) Ayman El-Faham et al. JOURNAL OF PEPTIDE SCIENCE
- Structural Basis of the Inhibition of Class A β-Lactamases and Penicillin-Binding Proteins by 6-β-Iodopenicillanate
- (2009) Eric Sauvage et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
- (2008) F. George Njoroge et al. ACCOUNTS OF CHEMICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started